Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22917247 | 0.87 | ACP3 (0.53) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4619753 | 0.84 | ACP3 (0.53) | ACP3MEN1KMT2ASMN1; SMN2HDAC8 | |
| SCHEMBL16807284 | 0.84 | L3MBTL1 (0.69) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23031983 | 0.82 | ACP3 (0.49) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7073016 | 0.82 | CNR1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29299753 | 0.81 | L3MBTL1 (0.51) | ACP3SMN1; SMN2ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL19347281 | 0.81 | ACP3 (0.47) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL465969 | 0.81 | TDP1 (0.61) | MEN1KMT2AL3MBTL1TDP1HDAC3 | |
| SCHEMBL28737154 | 0.80 | ACP3 (0.49) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16807273 | 0.80 | L3MBTL1 (0.62) | ACP3MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20030120088-A1 | Optically active azetidincarboxamide-coordinated transition metal complexes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6156940-A | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0435687-B1 | Process for isomerization of oxime ethers | SUMITOMO CHEMICAL CO (JP) | 1995-03-29 | — | — | EP | disclosed |
| US-5130486-A | A ketoximine ether isomerized using a Lewis acid metal halide | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0435687-A2 | Process for isomerization of oxime ethers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | PPIP5K2, INF2, IMPDH2 | ACP3 282/4885MEN1 898/4885KMT2A 2876/4885 |
| US-20030120088-A1 | Optically active azetidincarboxamide-coordinated transition metal complexes | AAAS, AP1M1, AP2A1 | ACP3 4192/4885MEN1 398/4885KMT2A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.